(Circulation. 2000;102:1755.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease
Primary Clinical Results of the ACADEMIC Study
From the Department of Medicine, Division of Cardiology, University of Utah, LDS Hospital, Salt Lake City, Utah.
Correspondence to J. Brent Muhlestein, MD, Division of Cardiology, LDS Hospital, 8th Ave & C St, Salt Lake City, Utah, 84143. E-mail ldbmuhle{at}ihc.com
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Chlamydia pneumoniae is associated with coronary artery disease (CAD), although its causal role is uncertain. A small preliminary study reported a >50% reduction in ischemic events by azithromycin, an antibiotic effective against C pneumoniae, in seropositive CAD patients. We tested this prospectively in a larger, randomized, double-blind study.
Methods and Results—CAD patients (n=302) seropositive to C
pneumoniae (IgG titers 
1:16) were randomized to placebo or
azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months. The
primary clinical end point included cardiovascular
death, resuscitated cardiac arrest, nonfatal myocardial infarction
(MI), stroke, unstable angina, and unplanned coronary
revascularization at 2 years. Treatment groups were
balanced, and azithromycin was generally well tolerated. During the
trial, 47 first primary events occurred (cardiovascular
death, 9; resuscitated cardiac arrest, 1; MI, 11; stroke, 3; unstable
angina, 4; and unplanned coronary
revascularization, 19), with 22 events in the
azithromycin group and 25 in the placebo group. There was no
significant difference in the 1 primary end point between the 2 groups
(hazard ratio for azithromycin, 0.89; 95% CI, 0.51 to 1.61;
P=0.74). Events included 9 versus 7 occurring within 6
months and 13 versus 18 between 6 and 24 months in the azithromycin and
placebo groups, respectively.
Conclusions—This study suggests that antibiotic therapy with
azithromycin is not associated with marked early reductions (50%) in
ischemic events as suggested by an initial published report.
However, a clinically worthwhile benefit (ie, 20% to 30%) is still
possible, although it may be delayed. Larger (several thousand
patient), longer-term (3 to 5 years) antibiotic studies are therefore
indicated.
Key Words: coronary disease • antibiotics • Chlamydia pneumoniae
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Apathogenic role for local inflammation in atherosclerotic plaque (inflammatory cytokines, macrophages, T lymphocytes) and systemic inflammation (eg, C-reactive protein [CRP]) in coronary artery disease (CAD) is being increasingly recognized.1 2 3 The stimuli for the inflammatory response are unknown, but they may include modified (oxidized) LDL and mechanical and toxic factors. Also, the possibility that infectious agents may stimulate vascular inflammation has been raised. 4 Specifically, cytomegalovirus5 and Chlamydia pneumoniae6 have been identified within atherosclerotic plaque; whether they play a causal role or are innocent commensals in atherogenesis is unknown. However, the possibility that chronic diseases thought previously to be noninfectious may indeed have an infectious component amenable to antibiotic therapy is dramatically exemplified by the response of peptic ulcer disease to antibiotics directed at Helicobacter pylori.7
C pneumoniae is a common, recently recognized etiologic agent of bronchitis and pneumonia.8 9 Between 50% and 70% of adults are seropositive.10 C pneumoniae, an obligate intracellular parasite, readily infects pulmonary mononuclear phagocytes and can replicate within and activate macrophages that migrate to and reside in atherosclerotic plaque.11
A serologic association between C pneumoniae and atherosclerosis has been extensively reported.12 13 14 15 16 17 Additionally, C pneumoniae is commonly detected within and isolated from atherosclerotic lesions.6 18 19 20 21 The possibility of a pathogenic role for C pneumoniae in CAD is further strengthened by studies in which intranasal infection of rabbits with C pneumoniae induced or accelerated atherosclerosis and antibiotic therapy inhibited atherogenesis.22 23
Chlamydiae are sensitive to macrolide antibiotics and
tetracyclines.24 Azithromycin, a new macrolide, is
rapidly absorbed, is widely distributed, achieves high and persistent
tissue concentrations (tissue half-life, 
72 hours), is well
tolerated, and has been effective in animal models.23
Thus, azithromycin and roxithromycin have been selected for human pilot
studies and ongoing major clinical coronary prevention
trials.25 26
Stimulated by these considerations, our own observational and animal data,6 23 and a small pilot antibiotic study in patients with CAD from Great Britain,25 we undertook a larger prospective, randomized, secondary prevention study. We have reported the 6-month laboratory results (showing a reduction in the global inflammatory marker index).27 Here, we report the 2-year primary clinical end-point results.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Design and Objectives
The study was designed as a randomized, double-blind, secondary prevention trial of azithromycin (3-month course) versus placebo in patients with documented CAD and seropositivity to C pneumoniae to test both laboratory and clinical objectives. The primary laboratory hypothesis was that compared with placebo, azithromycin therapy would reduce a global measure of systemic levels of the cluster of inflammatory markers C-reactive protein (CRP), interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-
at 3 (end
of therapy) and 6 months. The secondary laboratory hypothesis was that
antibiotic therapy would reduce antichlamydial IgG and IgA antibody
levels at 6 months. Methods and results of the laboratory hypotheses
have been reported previously.27 The clinical hypothesis was that at 2 years (primary end point), cardiovascular events would be reduced in the azithromycin compared with placebo groups. End-point events were defined as cardiovascular death (sudden death of unknown cause or death resulting from myocardial infarction [MI], congestive heart failure, stroke, or arrhythmia), resuscitated cardiac arrest, nonfatal MI (abnormal cardiac enzymes or new q-waves), stroke, unstable angina requiring hospitalization, and unplanned coronary interventions (catheter based or surgical). All primary end-point events were adjudicated by a blinded end-points committee. Other clinical objectives included the comparison by treatment group of all deaths, other cardiovascular hospitalizations or procedures, adverse experiences and drug discontinuations, and clinical infections. On the basis of the observation in our earlier report that inflammation markers decreased gradually, first becoming evident at 6 months, we hypothesized at our interim (6-month) analysis27 that subsequent (6- to 24-month) event rates might favor the azithromycin group.
Patient Qualification, Enrollment, and Randomization
Patients were qualified for the study if they had CAD documented
by a previous MI, bypass surgery, or >50% angiographic
stenosis of 1 major coronary artery; were >18 years
of age; had a life expectancy of >2 years; and gave written informed
consent. Exclusion criteria included the following: female patient
capable of childbearing without adequate birth control; NYHA functional
class III or IV congestive heart failure or left
ventricular ejection fraction <25%; MI within 5 days or
bypass surgery within 4 weeks or percutaneous
coronary intervention (any technique) within 3 months; planned
CABG or coronary intervention; significant comorbid illnesses,
including active malignancy, ongoing drug or alcohol abuse, renal
failure requiring dialysis, liver failure, etc, with a projected
life expectancy of <2 years; known intolerance to azithromycin; and
chronic macrolide (eg, erythromycin) or tetracycline use.
Patients were screened for C pneumoniae serum antibody
titers to provide 300 patients for enrollment with antichlamydial
IgG titers of 1:16 by microimmunofluorescence
(MIF) who met all study criteria and gave informed consent. Enrolled
patients were randomized 1:1 to the 2 treatment groups of azithromycin
or placeboy an unblinded, independent party (pharmacist) uninvolved in
clinical management except for provision of blinded drug supplies who
opened an envelope containing the drug assignment. The order of
randomization followed a permuted block design (alternating blocks of 4
and 6).
Supplies and Dosing of Drug and Placebo
Azithromycin, as 250-mg red capsules (Pfizer Laboratories), was
purchased from LDS Hospital Pharmacy. Matching placebo capsules were
purchased from Jolley’s Corner Pharmacy. Enrolled patients were to
initiate therapy with 2 capsules 500 mg/d for 3 days and then maintain
therapy with 2 capsules (500 mg) per week (Mondays) for 3 months, to be
taken 1 hour before or 2 hours after food.
Study Flow
Eligibility was determined during a screening visit. Eligible,
consenting patients had venous blood drawn and tested by MIF for
C pneumoniae antibodies. Patients with titers 1:16 were
seen 1 week later for randomization; baseline history and physical
examinations were completed, blood was drawn, a 12-lead ECG was
obtained, and study drug was dispensed. At 3, 6, and 12 months,
patients returned to review clinical status and drug compliance; blood
was sampled and an ECG was obtained. At 18 months and 2 years, clinical
follow-up was accomplished by telephone contact. Blinded adjudication
of all primary end points was performed by an end-points committee.
Each end point was reviewed by 2 cardiologists, and in cases of
differing opinions, the entire end-points committee discussed the case
until a consensus was obtained.
Laboratory Testing
Screening for anti–C pneumoniae antibody (IgG) used
a standard MIF test (MRL Diagnostics) on 1:16 diluted
serum. Other test methods have been previously
described.27
Statistical Analysis
Clinical event rate estimates were based on the pilot study of
Gupta et al,25 who reported a reduction in events from
28% to 8% by 18 months in treated patients with falling antibody
titers versus control subjects (ie, placebo-treated or untreated
patients with persistently elevated titers). Assuming a placebo event
rate of 28%, 150 patients per group provide 90% power to detect a
reduction in event rate caused by the study drug to 14.5% at 2 years
(primary clinical end point). The primary (null) hypothesis was that
there would be no difference between the azithromycin and placebo
groups in events; the alternate hypothesis was that changes would favor
antibiotic therapy. Assessment of clinical events used the
intention-to-treat approach. Groups were compared through the use of
survival methods (Kaplan-Meier) and the log-rank statistic. Cox
regression was used to determine univariate and multiple
variable hazard ratios and CIs. Categorical variables in the 2
groups were compared by 
2 testing; continuous
variables, by Student’s t or Mann-Whitney testing as
appropriate.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline Patient Characteristics
A total of 430 patients were screened, 333 (77%) had positive C pneumoniae serology, and 302 consented and were enrolled in the study, with 150 randomly assigned to receive azithromycin and 152 to receive placebo. Overall, patients were 64±10 (mean±SD) years of age (range, 30 to 88 years); 89% were male; and 60% had suffered a previous MI, 46% had undergone bypass surgery, and 46% had had percutaneous coronary interventions. Patient characteristics on admission were well balanced in the randomly assigned treatment groups (Table 1
).
|
Drug Tolerance and Compliance
These data have been reported previously.28
Compliance was good to excellent: 89% of active and 85% of placebo
patients followed the treatment plan without deviation. Drug was well
tolerated. Only 2 active therapy and 3 placebo patients permanently
discontinued therapy >2 weeks early. Overall, 36 (24%) of
azithromycin and 17 (11%) of placebo patients experienced some adverse
effect during the 3-month treatment period (P=0.003).
Adverse effects were believed to be possibly or probably drug related
in 25 active (17%) and 11 placebo (7%) patients (P=0.011).
They were usually mild, occasionally moderate, and most frequently
gastrointestinal (31 active, 12 placebo patients; P=0.002),
including nausea, diarrhea, or flatulence.
Clinical Cardiovascular Events
A total of 47 patients (15.6%) experienced 1 primary event over
the course of the trial; 22 patients were in the azithromycin group,
and 25 were in the placebo group. Event-free survival plots for the 2
treatment groups are shown in the Figure. There was no significant
difference in the combined primary end point between the 2 groups
(hazard ratio for azithromycin, 0.89; 95% CI, 0.51 to 1.61;
P=0.74). The distribution of events was 9 versus 7 events
within 6 months and 13 versus 18 events between 6 and 24 months in the
azithromycin and placebo groups, respectively.
|
The frequency of individual first primary events in the 2 treatment
groups was generally similar (Table 2). A
total of 63 events were noted during the study, including multiple
events in the same patient. These included 9
cardiovascular deaths, 1 resuscitated cardiac arrest,
10 MIs, 4 strokes, 15 unstable anginal episodes, and 24 unplanned
coronary revascularizations. A
nonsignificant reduction in total events was noted in the azithromycin
group (28 compared with 35 in the placebo group, P=0.35).
The frequency of each event type by treatment group is shown in Table 3. For none of the event types was there
a significant difference, although fewer unplanned coronary
revascularizations were performed in the
azithromycin group.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Summary of Study Results
This double-blind, randomized, secondary prevention study of moderately large size in CAD patients with serologic evidence of prior C pneumoniae exposure did not show a significant reduction in events by antibiotic (azithromycin) therapy at 2 years and is adequately powered to exclude a marked (>50%) early reduction in events, as reported in a previous study.25 Our earlier report of a gradual reduction in inflammatory markers with azithromycin, first appearing at 6 months,27 is consistent with the possibility that clinical effects (ie, reduced ischemic events) might be delayed until after the onset of the anti-inflammatory effect. This again contrasts with 2 smaller studies25 26 in which large early apparent benefits were reported. The reports based on these earlier, smaller studies thus appear to be overly enthusiastic; however, we believe our results should encourage rather than discourage additional studies based on more realistic expectations.
Pathophysiological Considerations
Our results are consistent with 3 possibilities: (1) a
noncausal role of C pneumoniae in CAD pathogenesis, (2) a
smaller benefit for antibiotic therapy (eg, 20% to 30% beneficial
effect), or (3) a causal role for C pneumoniae with the
present negative results explained by inefficiency of the
antibiotic regimen used. Additional studies (some underway) will be
necessary to distinguish among these possibilities. In our previous
report, 3 months of azithromycin therapy led to a gradual reduction in
the inflammatory marker index (composite of IL-1, IL-6, CRP, and
TNF-) compared with placebo that was first evident at 6 months. If
correct, this temporal pattern is more consistent with a
gradual ramping down of the inflammatory response to
atherosclerosis with plaque stabilization than an acute
nonspecific antibiotic effect (Infections requiring antibiotics were
reduced during the 3 months of active therapy). It might be speculated
that a reduction in clinical events could be delayed beyond 6 months.
The lower event rate in the azithromycin than placebo group after 6
months (13 versus 18), while not significant, is consistent
with this possibility.
This hypothesis is also consistent with currently suspected atherogenic mechanisms of C pneumoniae. C pneumoniae is capable of infecting both endothelial cells and macrophages.29 Activated foamy macrophages appear to play a critical role in the pathogenesis of unstable atherosclerotic plaques. It has been shown that cell cultures of monocytes may be transformed into activated macrophages through the addition of oxidized LDL to the culture medium.30 Kalayoglu and Byrne28 recently reported that in a similar model, infection with C pneumoniae significantly accelerates the development of foam cells and permits this transformation to occur at much lower levels of LDL in the culture medium. Additionally, they have reported that it is the lipopolysaccharide (LPS) component of the bacterial membrane that induces such an effect.31 It is possible that chlamydial LPS may persist within the atherosclerotic plaque for some time after the organism has been killed by antibiotic therapy, as was potentially demonstrated by findings from our study in a rabbit model.23 In this study, acceleration of intimal thickening was significantly reduced by 7 weeks of azithromycin therapy, but chlamydial antigens were still detectable. Although this may have occurred simply because of incomplete chlamydial eradication, it is possible that nonviable bacterial antigens remained.
Heat shock proteins (HSPs) have been demonstrated to be produced in association with stress of a variety of types.32 One in particular, HSP-60, has been shown to have independent atherogenic properties.33 Recently, Kol et al34 documented the colocalization of chlamydial HSP-60 within human atherosclerotic tissue. They also documented a correlation between HSP-60 and, in atherosclerotic foam cells, the production of matrix metalloproteinases, enzymes capable of degrading the strength of the atherosclerotic intimal cap.35 As in the case of chlamydial LPS, it is also possible that the bacterial HSP-60 may persist for some time after completion of antibiotic therapy and therefore result in a delayed clinical response. Certainly, further studies evaluating potential mechanisms whereby antibiotic therapy may result in a delayed clinical response would be of interest.
Alternatively, our data also are consistent with ineffective therapy by our antibiotic regimen against persistent, pathogenic C pneumoniae or a noncausal role of "commensal" C pneumoniae infections in coronary artery pathogenesis.
Comparisons With Previous and Current Antibiotic Trials
Our performance of a secondary prevention antibiotic study
was stimulated by our finding of a surprisingly high prevalence of
chlamydial antigen in coronary atherectomy specimens and by the
promising results of antibiotic therapy in our animal model and in a
pilot clinical study from the United Kingdom.6 23 25
Gupta et al25 stimulated interest in clinical antibiotic
trials with a pilot study in the United Kingdom: 60 survivors of acute
MI with persistently elevated antichlamydial antibody titers (1:64)
were randomized to receive placebo, a single 3-day course of
azithromycin (500 mg/d), or 2 courses 3 months apart. Compared with
patients in the placebo group plus a nonrandomized group with high
antibody titers, azithromycin-treated patients showed an apparent
reduction in cardiovascular events over 18 months (from
28% to 8%, P=0.03).
Subsequent to the initiation of our study, Gurfinkel et al26 also reported on a pilot antibiotic trial from Argentina, ROXIS: 202 patients presenting with unstable angina or non–Q-wave MI were randomized on hospital admission to roxithromycin, 150 mg twice daily, or placebo for 30 days. Rates of recurrent angina (2 versus 5), acute MI (0 versus 2), or death (0 versus 2), or any event (2 versus 9) tended to be reduced at 1 month (P=0.03). After 6 months of follow-up, there remained a nominal difference in cardiovascular events between the treated and control groups, but the difference was no longer statistically significant (8.7% versus 14.6%, P=0.26).36 This study raised the possibility that antibiotic therapy might provide specific early benefit in the setting of an acute coronary syndrome.
Our study results contrast with these earlier studies in several ways. We randomized a much larger sample than Gupta et al (300 compared with 60) and gave more intensive antibiotic therapy (7.5 compared with 1.5 to 3.0 g azithromycin over 3 months) but did not demonstrate a dramatic early reduction in clinical events.27 In fact, we observed no trend toward benefit until after 12 to 18 months of follow-up, the end point of clinical follow-up in the study of Gupta et al.
The study of Gurfinkel et al26 was of intermediate size (200 patients) and used roxithromycin; their report of a trend in adverse events reduction (2 versus 9) at 1 month also stands in contrast to our study. It should be stressed, however, that Gurfinkel et al studied acute coronary syndrome patients and a different antibiotic regimen, so differences in outcome could occur on the basis of differences in the patient population and treatment. Between 1 and 6 months, no further separation of event curves was observed (differences no longer nominally significant); longer-term follow-up has not been reported.
Although not definitive, these pilot trials offer the hope that antibiotic therapy targeted against C pneumoniae might be useful in the secondary prevention of cardiovascular disease and that this deserves further testing. In this regard, 2 large antibiotic secondary trials are underway that are adequately powered to determine a clinically important effect on cardiovascular events. Each uses once-a-week azithromycin. The Weekly Intervention With Zithromax Against Atherosclerotic-Related Disorders (WIZARD) trial, sponsored by Pfizer, is enrolling >7000 patients with prior MI and C pneumoniae seropositivity, treating them for 3 months, and observing events over 2.5 years. The Azithromycin Coronary Events Study (ACES) trial, sponsored by the NHLBI, is enrolling >4000 patients with CAD regardless of antibody status, treating them for 1 year, and following them up for 4 years. These trials should provide more definitive answers about the infectious hypothesis of CAD and treatment opportunities.
Study Strengths, Limitations, and Implications
This study adds substantially to the small amount of previous work
relating C pneumoniae to atherosclerosis in
humans and antibiotic therapy directed at chlamydia in patients with
CAD manifestations.25 26 The validity of the
statistical inferences of the study is bolstered by its prospective,
randomized, double-blind design and moderately large size. However, the
power of the study was adequate only for large changes in clinical end
points (ie, for 50% reductions) over 2 years. We have excluded such
large effects with confidence but have left open the possibility of
more modest, clinically worthwhile benefits (eg, 20% to 30%
reductions).
The optimal dose and duration of therapy are unknown. C pneumoniae in a persistent, metabolically inactive state might be resistant to short-term and nonbacteriocidal antibiotic therapy. Longer-term and/or intermittent (eg, monthly) treatment with azithromycin or another agent may be required to achieve worthwhile benefit. Beneficial effects, if seen, may be due to either a specific antichlamydial action or a more general anti-infectious or anti-inflammatory effect. Consequently, it is not expected that this study or any other single antibiotic-related clinical trial can definitively confirm or reject the hypothesis that atherosclerosis, an inflammatory disease, also contains an infectious component. It does, however, add to the growing body of knowledge regarding this hypothesis.
Conclusions
In a study of 302 CAD patients followed up for 2 years, a 3-month
course of azithromycin was not associated with an overall reduction in
cardiovascular events compared with placebo. Larger,
longer-term studies are needed to assess the potential of worthwhile
but more modest and delayed benefits of antibiotic therapy in CAD than
previously reported. The role of infectious agents in CAD is a
legitimate area of research, but a causal role for infection remains a
hypothesis to be proved, and antibiotic therapy for patients with CAD
is not yet indicated.
|
Acknowledgments |
|---|
The study was supported in part by a grant from the Deseret Foundation, LDS Hospital, Salt Lake City, Utah. We thank members of the Data and Safety Monitoring Committee: Sheldon Litwin, MD; Jay Jacobsen, MD; and Al Hallstrom, PhD.
Received December 28, 1999; revision received May 19, 2000; accepted May 19, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44.
2.
Ross R. Atherosclerosis: an
inflammatory disease. N Engl J Med. 1999;340:115–26.
3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791–804.[Medline] [Order article via Infotrieve]
4.
Libby P, Egan D, Skarlatos S. Roles of infectious
agents in atherosclerosis and restenosis: an
assessment of the evidence and need for future research.
Circulation. 1997;96:4095–4103.
5. Melnick JL, Hu C, Burek J, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol. 1994;42:170–174.[Medline] [Order article via Infotrieve]
6. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555–1561.[Abstract]
7.
Walsh JH, Peterson WL. The treatment of
Helicobacter pylori infection in the management of peptic
ulcer disease. N Engl J Med. 1995;333:984–991.
8. Grayston JT, Duo CC, Wang SP, et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315:161–168.[Abstract]
9. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;165:757–761.
10. Aldous MB, Grayston JT, Wang SP, et al. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966–79. J Infect Dis. 1992;166:646–69.[Medline] [Order article via Infotrieve]
11. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620.[Abstract]
12. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986.[Medline] [Order article via Infotrieve]
13. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278.
14.
Linnanmaki E, Leinonen M, Mattila K, et al.
Chlamydia pneumoniae specific circulating immune complexes
in patients with chronic coronary heart disease.
Circulation. 1993;87:1130–1134.
15.
Thom DH, Grayston JT, Siscovick DS, et al. Association
of prior infection with Chlamydia pneumoniae and
angiographically demonstrated coronary heart disease.
JAMA. 1992;268:68–72.
16. Grayston JT, Kuo CC, Campbell LA, et al. Chlamydia pneumoniae, strain TWAR, and atherosclerosis. Eur Heart J. 1993;14:66–71.
17.
Anderson JL, Carlquist JF, Muhlestein JB, et al.
Evaluation of C-reactive protein, an inflammatory marker, and
infectious serology as risk factors for coronary artery disease
and myocardial infarction. J Am Coll Cardiol. 1998;32:35–41.
18. Shor A, Kuo C-C, Patent DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks in atheromatous plaques. S Afr Med J. 1992;82:158–161.[Medline] [Order article via Infotrieve]
19. Kuo C-C, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841–849.[Medline] [Order article via Infotrieve]
20. Grayston JT, Kuo C-C, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995;95:3397–3400.
21.
Ramirez JA. Isolation of Chlamydia
pneumoniae from the coronary artery of a patient with
coronary atherosclerosis: the Chlamydia
pneumoniae/Atherosclerosis Study Group. Ann
Intern Med. 1996;125:979–982.
22. Fong IW, Chiu B, Vira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48–52.[Abstract]
23.
Muhlestein JB, Anderson JL, Hammond EH, et al.
Infection with Chlamydia pneumoniae accelerates the
development of atherosclerosis and treatment with
azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636.
24.
Chirgwin K, Roblin PM, Hammerschlag MR. In vitro
susceptibilities of Chlamydia pneumoniae (Chlamydia sp.
strain TWAR). Antimicrob Agents Chemother. 1989;33:1634–1635.
25.
Gupta S, Leatham EW, Carrington M, et al. Elevated
Chlamydia pneumoniae antibodies,
cardiovascular events, and azithromycin in male
survivors of myocardial infarction. Circulation. 1997;96:404–407.
26. Gurfinkel E, Bozovich G, Daroca A, et al, for the ROXIS Study Group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407.[Medline] [Order article via Infotrieve]
27.
Anderson JL, Muhlestein JB, Carlquist J, et al.
Randomized secondary prevention trial of azithromycin in patients with
coronary artery disease and serological evidence for Chlamydia
pneumoniae infection: the Azithromycin in Coronary Artery
Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC)
study. Circulation. 1999;99:1540–1547.
28. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;177:725–729.
29. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620.
30. Yang X, Galeano NF, Szabolcs M, et al. Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, viability and nitric oxide synthesis. J Nutr. 1996;126(suppl 4):1072S–1075S.
31.
Kalayoglu MV, Byrne GI. A Chlamydia
pneumoniae component that induces macrophage foam cell
formation is chlamydial lipopolysaccharide. Infect
Immun. 1998;66:5067–5072.
32. Udelsman R, Blake MJ, Stagg CA, et al. Vascular heat shock protein expression in response to stress: endocrine and autonomic regulation of this age-dependent response. J Clin Invest. 1993;91:465–473.
33. Wick G, Kleindienst R, Schett G, et al. Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis. Int Arch Allergy Immunol. 1995;107:130–131.[Medline] [Order article via Infotrieve]
34.
Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial
heat shock protein 60 localizes in human atheroma and
regulates macrophage tumor necrosis factor- and matrix
metalloproteinase expression. Circulation. 1998;98:300–307.
35. Kol A, Bourcier T, Lichtman AH, et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest. 1999;103:571–577.[Medline] [Order article via Infotrieve]
36.
Gurfinkel E, Bozovich G, Beck E, et al. Treatment with
the antibiotic roxithromycin in patients with acute non-Q-wave
coronary syndromes: the final report of the ROXIS Study.
Eur Heart J. 1999;20:121–127.
This article has been cited by other articles:
 |
|
 |
|
  S. Amar, S.-c. Wu, and M. Madan Is Porphyromonas gingivalis Cell Invasion Required for Atherogenesis? Pharmacotherapeutic Implications J. Immunol., February 1, 2009; 182(3): 1584 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K.-H. Chow, B. Razani, and G. Cheng Innate immune system regulation of nuclear hormone receptors in metabolic diseases J. Leukoc. Biol., August 1, 2007; 82(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Baker and K. A. Couch Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Krack, R. Sharma, H. R. Figulla, and S. D. Anker The importance of the gastrointestinal system in the pathogenesis of heart failure Eur. Heart J., November 2, 2005; 26(22): 2368 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Andraws, J. S. Berger, and D. L. Brown Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials JAMA, June 1, 2005; 293(21): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson Infection, Antibiotics, and Atherothrombosis -- End of the Road or New Beginnings? N. Engl. J. Med., April 21, 2005; 352(16): 1706 - 1709. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Voils, M. E Evans, M. T Lane, R. H Schosser, and R. P Rapp Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases Ann. Pharmacother., January 1, 2005; 39(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wells, A. G. Mainous III, and L. M. Dickerson Antibiotics for the Secondary Prevention of Ischemic Heart Disease: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, October 25, 2004; 164(19): 2156 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Progression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity Circulation, March 2, 2004; 109(8): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Burnett, S. Durrani, E. Stabile, M. Saji, C. W. Lee, T. D. Kinnaird, E. P. Hoffman, and S. E. Epstein Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes Circulation, February 24, 2004; 109(7): 893 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Madjid, M. Naghavi, S. Litovsky, and S. W. Casscells Influenza and Cardiovascular Disease: A New Opportunity for Prevention and the Need for Further Studies Circulation, December 2, 2003; 108(22): 2730 - 2736. [Full Text] [PDF]
|
|
|
|
|
|
C. M. O'Connor, M. W. Dunne, M. A. Pfeffer, J. B. Muhlestein, L. Yao, S. Gupta, R. J. Benner, M. R. Fisher, and T. D. Cook Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial JAMA, September 17, 2003; 290(11): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Karter, D. H. Thom, J. Liu, H. H. Moffet, A. Ferrara, and J. V. Selby Use of Antibiotics Is Not Associated With Decreased Risk of Myocardial Infarction Among Patients With Diabetes Diabetes Care, July 1, 2003; 26(7): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, H. Friedman, M. Yamamoto, K. Yasuda, and Y. Yamamoto Chlamydia pneumoniae Resists Antibiotics in Lymphocytes Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1972 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Grayston Antibiotic Treatment of Atherosclerotic Cardiovascular Disease Circulation, March 11, 2003; 107(9): 1228 - 1230. [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, S. Schneider, B. Frilling, K. Seidl, U. Tebbe, M. Weber, M. Gottwik, E. Altmann, F. Seidel, J. Rox, et al. Antibiotic Therapy After Acute Myocardial Infarction: A Prospective Randomized Study Circulation, March 11, 2003; 107(9): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Spence and J. Norris Infection, Inflammation, and Atherosclerosis Stroke, February 1, 2003; 34(2): 333 - 334. [Full Text] [PDF]
|
|
|
|
|
|
B. D. Horne, J. B. Muhlestein, J. F. Carlquist, T. L. Bair, T. E. Madsen, N. I. Hart, J. L. Anderson, and for the Intermountain Heart Collaborative (IHC) St Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease Circulation, January 21, 2003; 107(2): 258 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Forrester Prevention of Plaque Rupture: A New Paradigm of Therapy Ann Intern Med, November 19, 2002; 137(10): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Circulation, November 5, 2002; 106(19): 2428 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Delahaye, E. P. McFadden, and G. de Gevigney The scourge of coronary disease in diabetic patients: will antibiotics sweeten the pill? Eur. Heart J., October 2, 2002; 23(20): 1557 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
A. F.M. Stone, M. A. Mendall, J.-C. Kaski, T. M. Edger, P. Risley, J. Poloniecki, A. J. Camm, and T. C. Northfield Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) Circulation, September 3, 2002; 106(10): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Kerrigan, I. Douglas, A. Wray, J. Heath, M. F. Byrne, D. Fitzgerald, and D. Cox A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation Blood, June 28, 2002; 100(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stollberger and J. Finsterer Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215. [Full Text] [PDF]
|
|
|
|
|
|
P. Lavallee, V. Perchaud, M. Gautier-Bertrand, D. Grabli, and P. Amarenco Association Between Influenza Vaccination and Reduced Risk of Brain Infarction Stroke, February 1, 2002; 33(2): 513 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
S. C. Johnston, L. M. Messina, W. S. Browner, M. T. Lawton, C. Morris, and D. Dean C-Reactive Protein Levels and Viable Chlamydia pneumoniae in Carotid Artery Atherosclerosis Stroke, December 1, 2001; 32(12): 2748 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Farzaneh-Far, J. Rudd, and P. L Weissberg Inflammatory mechanisms: Ischaemic heart disease Br. Med. Bull., October 1, 2001; 59(1): 55 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gieffers, H. Fullgraf, J. Jahn, M. Klinger, K. Dalhoff, H. A. Katus, W. Solbach, and M. Maass Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment Circulation, January 23, 2001; 103(3): 351 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 No Effect from Azithromycin in Patients with Coronary Disease Journal Watch (General), October 20, 2000; 2000(1020): 4 - 4. [Full Text]
|
|
|
|
|
|
J. Sinisalo, K. Mattila, V. Valtonen, O. Anttonen, J. Juvonen, J. Melin, H. Vuorinen-Markkola, M. S. Nieminen, and for the Clarithromycin in Acute Coronary Syndrome Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non-Q-Wave Coronary Syndrome Circulation, April 2, 2002; 105(13): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||